Document Detail


Atrial fibrillation : New anticoagulants and antiarrhythmic drugs.
MedLine Citation:
PMID:  22382136     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke. Several new anticoagulants have recently been introduced as alternatives to vitamin-K antagonists for prophylaxis of ischemic stroke and tested in phase-3 studies for efficacy and safety. Identifying patients who will profit in particular from the new anticoagulant therapy is crucial to the clinical application of these drugs. Vernakalant and dronedarone are new antiarrhythmic drugs for rhythm control of atrial fibrillation. However, therapeutic efficacy of the new agents still has to be proven.
Authors:
E Kaya; G Frommeyer; G Mönnig; L Eckardt
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-2
Journal Detail:
Title:  Herz     Volume:  -     ISSN:  1615-6692     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7801231     Medline TA:  Herz     Country:  -    
Other Details:
Languages:  GER     Pagination:  -     Citation Subset:  -    
Affiliation:
Abteilung für Rhythmologie, Department für Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, 48149, Münster, Deutschland, elif.kaya@ukmuenster.de.
Vernacular Title:
Vorhofflimmern : Neue Antiarrhythmika und Antikoagulanzien.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Decreased c-Jun expression correlates with impaired spinal motoneuron regeneration in aged mice foll...
Next Document:  Interventional electrophysiology in cardiac MRI : What is the current status?